Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Conditions

• Diaphragm Injury

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Tofacitinib 10 MG [Xeljanz] — DRUG
  administered twice daily for two days
• Placebo to match Tofacitinib — DRUG
  administered twice daily for two days

Study Details

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Key Dates

Start date

Sep 3, 2019

Status verified

Nov 2024

Primary completion

Nov 30, 2025

Completion

Nov 30, 2026

Study Design

Enrollment

70 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Tofacitinib
  Patient will receive two days treatment with tofacitinib prior to the surgery.
• Placebo Comparator: Placebo
  Patient will receive two days treatment with placebo prior to the surgery.

Primary Outcome Measure

Prevention of ventilator-induced diaphragm dysfunction by JAK inhibition [ Time Frame: 5-6 years ]

Central Contacts

• Cheyenne A Clinical Research Coordinator, B.S, M.S
  3107201689
  [email protected]

Locations (1)

Find similar trials in Stanford, CA

Related Studies

• Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
  Recruiting · University of California, Los Angeles · Los Angeles, California